JESDUVROQ Drug Patent Profile

Which patents cover Jesduvroq, and when can generic versions of Jesduvroq launch?

Jesduvroq is a drug marketed by Glaxosmithkline and is included in one NDA. There are six patents protecting this drug.

This drug has forty-four patent family members in thirty-one countries.

The generic ingredient in JESDUVROQ is daprodustat. One supplier is listed for this compound. Additional details are available on the daprodustat profile page.

DrugPatentWatch^® Generic Entry Outlook for Jesduvroq

Jesduvroq will be eligible for patent challenges on February 1, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 11, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for JESDUVROQ

International Patents:	44
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	46
Clinical Trials:	1
Patent Applications:	120
Drug Prices:	Drug price information for JESDUVROQ
What excipients (inactive ingredients) are in JESDUVROQ?	JESDUVROQ excipients list
DailyMed Link:	JESDUVROQ at DailyMed

See drug prices for JESDUVROQ

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for JESDUVROQ

Constraining patent/regulatory exclusivity:

8,324,208

NDA:

216951

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for JESDUVROQ

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
USRC Kidney Research	Phase 4
GlaxoSmithKline	Phase 4

See all JESDUVROQ clinical trials

Pharmacology for JESDUVROQ

Drug Class	Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor
Mechanism of Action	Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors

US Patents and Regulatory Information for JESDUVROQ

JESDUVROQ is protected by six US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 8,324,208.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-005	Feb 1, 2023		DISCN	Yes	No	11,649,217		Y
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-004	Feb 1, 2023		DISCN	Yes	No
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-005	Feb 1, 2023		DISCN	Yes	No	11,643,397			Y
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-005	Feb 1, 2023		DISCN	Yes	No	11,117,871		Y	Y
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-001	Feb 1, 2023		DISCN	Yes	No	11,117,871		Y	Y
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-003	Feb 1, 2023		DISCN	Yes	No	11,649,217		Y
Glaxosmithkline	JESDUVROQ	daprodustat	TABLET;ORAL	216951-004	Feb 1, 2023		DISCN	Yes	No	8,557,834

International Patents for JESDUVROQ

When does loss-of-exclusivity occur for JESDUVROQ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Jordan

Morocco

Portugal

South Africa

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering JESDUVROQ around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2018330994
Canada	3112277
China	111093668
European Patent Office	3682884	FORME CRISTALLINE DE GSK1278863 ET SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION PHARMACEUTIQUE (CRYSTAL FORM OF GSK1278863 AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF)
Spain	2980121
Japan	2020533396	ＧＳＫ１２７８８６３の結晶形及びその製造方法並びに医薬用途
Japan	2025041663	ＧＳＫ１２７８８６３の結晶形及びその製造方法並びに医薬用途 (CRYSTALLINE FORMS OF GSK1278863, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF)

Last updated: April 24, 2026

JESDUVROQ: What do the market dynamics and financial trajectory indicate?

No actionable market-dynamics or financial-trajectory analysis can be produced for JESDUVROQ from the information available in this workspace.

The identifier “JESDUVROQ” does not map to a clearly attributable, publicly verifiable pharmaceutical product (brand name, INN/USAN stem, manufacturer, marketing authorization, label geography, NDC/HCPCS, or patent family) in the data available here. Without a confirmed drug identity, there is no reliable way to determine commercial launch status, pricing, revenue pathway, channel structure, competitor landscape, payer access, or patent/market-exclusivity timeline that would meet a professional patent-analysis standard.

---

What can be concluded about market dynamics?

None. A market-dynamics assessment requires at minimum: (i) the marketed product identity (name and active ingredient), (ii) labeled indication(s), (iii) approval geography and dates, and (iv) the relevant competitive set. Those inputs are not available for JESDUVROQ in this workspace.

---

What can be concluded about financial trajectory?

None. A financial-trajectory assessment requires: (i) validated product-to-revenue linkage (company disclosures, guidance, segment reporting), (ii) sales/market share history, and (iii) pricing and reimbursement pathway. Those inputs are not available for JESDUVROQ in this workspace.

---

Key Takeaways

• No validated product mapping exists here for JESDUVROQ, so no defensible market dynamics conclusions can be made.
• No verified commercial/revenue trail can be linked to JESDUVROQ, so no financial trajectory can be assessed.
• A professional analysis cannot be produced without confirmed identity-to-market linkage.

---

FAQs

1. What is JESDUVROQ?
   The workspace does not contain enough information to identify JESDUVROQ as a specific marketed pharmaceutical product.

2. Is JESDUVROQ approved in major markets (US/EU/JP)?
   Approval status and geography are not provided here.

3. What indication does JESDUVROQ target?
   Indication details are not provided here.

4. Who manufactures JESDUVROQ and under what brand?
   Manufacturer and brand mapping are not provided here.

5. Can revenue, pricing, or sales trajectory be forecast?
   Not from the information available in this workspace.

---

References

[1] No sources were available in the workspace to cite.

DrugChatter Q&A for JESDUVROQ

How does Jesduvroq treat anemia in dialysis?